Can Lilly’s milestone-heavy deal for Adverum reshape how Big Pharma acquires gene therapy platforms?

Why milestone-based M&A is becoming the default for risky biotech deals in 2025

Eli Lilly and Company’s agreement to acquire Adverum Biotechnologies is not just another biotech buyout—it’s a case study in how Big Pharma is rewriting deal structures to fit a high-risk, capital-constrained innovation landscape. The offer, valued at up to $12.47 per share, consists of a modest $3.56 in cash and a much larger, milestone-linked payout of $8.91 through non-tradable contingent value rights (CVRs). That setup, while headline-grabbing, reflects a deeper shift in how biotech M&A is now functioning—especially when it involves unapproved gene therapies.

In 2023 and 2024, all-cash biotech deals were the exception rather than the rule. With rising interest rates, regulatory uncertainty, and a string of high-profile clinical disappointments in gene therapy, acquirers have grown more cautious. CVRs offer a convenient way to hedge execution risk while maintaining upside if a candidate succeeds. But the non-transferable nature of these CVRs in the Lilly–Adverum deal sets it apart, forcing long-term alignment between the acquirer and legacy investors in a way public shareholders don’t always appreciate.

How Adverum’s Ixo-vec positioned itself as a one-shot disruptor for wet AMD

At the heart of the transaction is Ixo-vec, Adverum’s lead clinical-stage asset targeting wet age-related macular degeneration (wAMD)—a chronic, sight-threatening condition that currently requires frequent anti-VEGF injections. This treatment burden creates an opportunity for a more durable, patient-friendly solution, and Ixo-vec was designed exactly for that. It delivers a gene payload via a proprietary AAV.7m8 vector in a single intravitreal injection, aiming to provide continuous therapeutic expression of aflibercept, the same protein targeted by Eylea and other anti-VEGF agents.

This “one-and-done” model, if proven clinically and commercially viable, could capture market share from incumbent biologics while unlocking pricing power due to its convenience. However, gene therapy in ophthalmology is still a minefield. Adverum itself faced early safety setbacks and had to tweak vector design, dosing strategy, and patient selection criteria. By 2025, the company had made clinical progress—but not enough to de-risk the asset fully. That’s where Lilly saw an opportunity to step in.

Why Lilly structured the deal to cap its downside while keeping full upside optionality

The cash component of the deal—just $3.56 per share—may appear underwhelming at first glance. But when coupled with the $8.91 in potential CVRs, the deal becomes an elegant compromise between immediate value and long-term belief in the asset. The two CVR triggers are ambitious yet grounded in clinical and commercial logic. One is tied to U.S. regulatory approval before the seventh anniversary of the deal closing. The other hinges on Ixo-vec reaching $1 billion in annual worldwide sales within ten years.

This isn’t a simple earnout; it’s a long-duration options contract on an asset that still needs to clear regulatory, manufacturing, and adoption hurdles. For Lilly, the benefit is clear—it acquires a platform with disruptive potential and no near-term drag on its P&L if things go sideways. For Adverum’s investors, the math is trickier. If milestones are missed, the total return is capped at the upfront price. If they’re hit, the full $12.47 valuation turns this into a blockbuster exit.

What this deal reveals about biotech capital constraints and strategic pivots

Before this acquisition, Adverum was already running on a limited runway. According to company filings, it had enough cash to fund operations only through October 2025. Without a buyout, it faced two unappealing options: raise capital through dilutive equity issuance or enter strategic partnerships that might limit future upside. The Lilly bridge financing of up to $65 million provided a lifeline, enabling continued development of Ixo-vec while the transaction moved toward closing.

This kind of pre-close support has become more common in biotech deals where the seller is cash-strapped. It allows the acquirer to maintain asset momentum and avoid value destruction from program pauses. But it also underscores the weak negotiating position of many small-cap biotech firms. Adverum’s board, after reviewing alternatives, clearly concluded that Lilly’s offer was the best risk-adjusted path forward. For shareholders, that means accepting a binary future: either Ixo-vec succeeds—and they’re handsomely rewarded—or the base cash payout becomes the effective floor.

How non-transferable CVRs are changing shareholder dynamics in post-deal biotech

One unusual feature of this transaction is the non-transferable nature of the CVRs. In many past deals, CVRs could be traded on secondary markets, allowing investors to monetize potential milestones early or pass on risk. In Lilly’s deal, that option is gone. Shareholders must hold the CVR until milestones are met or the timeline expires. This forces retail and institutional investors alike to stay invested in the outcome of a program they no longer control or influence.

The implications are significant. For funds with defined holding periods or liquidity mandates, non-tradable CVRs may be a deterrent, especially if the payout window extends five to ten years. That could reduce participation in similar deals unless exit options are offered. However, from an acquirer’s perspective, locking in CVR holders ensures better alignment and reduces the chance of speculative behavior distorting asset expectations.

Is Lilly building a stealth platform in gene therapy—and is ophthalmology just the start?

Lilly has historically been quieter than peers like Roche, Novartis, or Pfizer when it comes to gene therapy. But this deal—and the growing number of assets in its pipeline—suggests that the company is laying the foundation for a broader gene therapy platform. Adverum brings more than just Ixo-vec; its capsid library, manufacturing protocols, and vector design experience could be leveraged across other indications. That includes not only ophthalmology, but potentially rare diseases and neurology, where vector optimization remains a key bottleneck.

What’s also notable is Lilly’s timing. The broader biotech sector has been under pressure, making platform acquisitions more affordable. By focusing on a single-asset company with additional tech stack value, Lilly may be pursuing a de-risked roll-up strategy: buy clinical-stage players at a discount, integrate selectively, and use internal development to expand indications over time.

What should investors watch for next—and how will this shape M&A deal structures ahead?

For public market investors, the next few quarters will be about tracking clinical and regulatory progress on Ixo-vec. If Lilly fast-tracks the program and files with the FDA earlier than expected, it could signal high internal conviction and increase the probability of the first CVR being paid. Commercial strategy disclosures—such as pricing models, market access plans, or salesforce alignment—will also offer clues about the likelihood of reaching the $1 billion sales threshold.

More broadly, expect to see this deal cited as a blueprint for biotech M&A in the second half of 2025. As more platforms come under financial pressure, milestone-linked buyouts with optionality and bridge financing could become the norm. For pharma acquirers, this approach limits downside. For biotech boards and investors, it may be the only viable way to preserve value while securing development continuity.

Why this deal may be more about platform leverage than immediate revenue

While the market is focused on Ixo-vec and the $12.47 headline price, Lilly may view the real win as platform leverage. Adverum’s AAV.7m8 vector, scalable manufacturing capabilities, and clinical data infrastructure provide Lilly with tools it can apply across its gene therapy ambitions. The ophthalmology entry point may be strategic—it’s a contained delivery environment with clearly defined endpoints, offering a more predictable regulatory path than systemic gene therapies.

If Lilly successfully brings Ixo-vec to market, it could catalyze a broader wave of investment into next-gen ocular gene therapies, possibly even reshaping how ophthalmology is approached in pharma portfolios. But even if Ixo-vec stalls, the knowledge and infrastructure acquired in this deal will likely outlive the asset.

Key takeaways: What the Lilly–Adverum acquisition signals for biotech M&A and gene therapy strategy

• Lilly’s acquisition of Adverum Biotechnologies is structured for up to $12.47 per share, combining a $3.56 upfront cash payout with $8.91 tied to long-term CVR milestones.

• The deal centers around Ixo‑vec, a one‑time gene therapy candidate aiming to reduce or eliminate repeated anti‑VEGF injections in wet AMD patients.

• The CVRs are non‑transferable, meaning shareholders cannot trade or exit the milestone-linked value, locking them into Lilly’s execution timeline.

• Adverum had limited cash runway into late 2025, making the acquisition and Lilly’s bridge financing necessary to maintain trial progress and avoid dilution.

• For Lilly, the acquisition represents a strategic expansion into ophthalmology gene therapy, with potential platform leverage beyond Ixo‑vec.

• The deal reflects a broader shift toward milestone‑based M&A structures as Big Pharma hedges clinical and commercial risk in capital‑intensive therapeutic areas.

• The defining investor question is the probability of regulatory approval and $1B+ annual revenue, which dictates whether the CVR value will be realized.

• Success of this deal may influence how future biotech transactions in 2025–2026 are priced, particularly in gene therapy, ophthalmology, and platform-oriented M&A.